New York, Dec. Feb. 27, 2022 (GLOBE NEWSWIRE) — Insilico Medicine (“Insilico”), an end-to-end artificial intelligence (AI)-focused drug discovery company, today announced that the drug discovery team Company has named a preclinical candidate targeting KAT6A for the treatment of ER+/HER2- breast cancer using its end-to-end Pharma.AI platform. The Company has now named eight preclinical candidates in 2022.
According to statistics released by the International Agency for Research on Cancer (IARC), breast cancer overtook lung cancer as the most commonly diagnosed cancer and the fifth leading cause of cancer death worldwide in 2020. ER+/ HER2 – Breast cancer is the most common subtype and hormone therapy in combination with CDK4/6 inhibitors is the standard treatment for this population with advanced or metastatic disease. However, the overall reported response rate is less than 50%, indicating a huge unmet medical need.
“KAT6A is emerging as an attractive epigenetic target for ER+/HER2- breast cancer, and we are committed to rapidly advancing CCP to clinical trial to assess its efficacy in the clinic,” said Feng Ren, Ph. .D., Co. CEO and Scientific Director of Insilico Medicine.
KAT6A is a histone (lysine) acetyltransferase (HAT), playing an important role in cell cycle progression, maintenance of neuronal stem cells, and hematopoietic development. In breast cancer, KAT6A is amplified in frame of the 8p11 amplicon in approximately 10-15% of the population and modulates the level of estrogen receptor (ER) expression. Therefore, targeting the oncogene KAT6A should provide a promising therapy for patients with ER+/HER2- breast cancer.
The preclinical compound is a selective KAT6A inhibitor generated with the help of Insilico’s AI drug design platform, Chemistry42. It shows strong in vitro inhibitory activity and live efficacy in ER+/HER2- breast cancer models and demonstrated significant efficacy in tumor models derived from patients who relapsed on multiple prior lines of therapy. He also satisfied in vitro ADME properties and live pharmacokinetic profile. Insilico has initiated an Investigational New Drug (IND) allowing the study of the compound to advance this internally developed program to the clinical stage.
“The nomination of the preclinical candidate for the KAT6A target strengthens our growing oncology pipeline, further validating the strength of our proprietary AI platform,” said Alex Zhavoronkov, PhD, Founder and CEO of Insilico Medicine. “We are excited to see how the Chemistry42 next-generation AI platform, which we provide to our partners, is accelerating our own drug discovery efforts.”
Powered by its end-to-end Pharma.AI platform, Insilico has delivered eight preclinical candidates with AI-discovered therapies from new target with a new structure and AI-designed therapies of known targets with desired properties over the past 12 months, spanning multiple disease areas, including immuno-oncology, inflammation and COVID-19[feminine]. He also entered Phase I clinical trials with its first internally developed program for fibrosis in New Zealand and China.
About Insilico Medicine
Insilico Medicine, an end-to-end clinical-stage artificial intelligence (AI)-focused drug discovery company, connects clinical trial biology, chemistry and analytics using novel AI systems. generation. The company has developed AI platforms that use deep generative models, reinforcement learning, transformers and other modern machine learning techniques for the discovery of new targets and the generation of new molecular structures with the properties desired. Insilico Medicine develops breakthrough solutions to discover and develop innovative drugs against cancer, fibrosis, immunity, central nervous system diseases, infectious diseases, autoimmune diseases and age-related diseases.
Website: www.insilico.co m
Contact: media@insilico.com
Brita Belli Insilico Medicine 475-225-0843 brita@insilico.com
Copyright 2022 GlobeNewswire, Inc.
0 Comments